Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging.
Sci Rep
; 14(1): 11959, 2024 05 25.
Article
en En
| MEDLINE
| ID: mdl-38796495
ABSTRACT
AGuIX, a novel gadolinium-based nanoparticle, has been deployed in a pioneering double-blinded Phase II clinical trial aiming to assess its efficacy in enhancing radiotherapy for tumor treatment. This paper moves towards this goal by analyzing AGuIX uptake patterns in 23 patients. A phantom was designed to establish the relationship between AGuIX concentration and longitudinal ( T 1 ) relaxation. A 3T MRI and MP2RAGE sequence were used to generate patient T 1 maps. AGuIX uptake in tumors was determined based on longitudinal relaxivity. AGuIX (or placebo) was administered to 23 patients intravenously at 100 mg/kg 1-5 hours pre-imaging. Each of 129 brain metastases across 23 patients were captured in T 1 maps and examined for AGuIX uptake and distribution. Inferred AGuIX recipients had average tumor uptakes between 0.012 and 0.17 mg/ml, with a mean of 0.055 mg/ml. Suspected placebo recipients appeared to have no appreciable uptake. Tumors presented with varying spatial AGuIX uptake distributions, suspected to be related to differences in accumulation time and patient-specific bioaccumulation factors. This research demonstrates AGuIX's ability to accumulate in brain metastases, with quantifiable uptake via T 1 mapping. Future analyses will extend these methods to complete clinical trial data (~ 134 patients) to evaluate the potential relationship between nanoparticle uptake and possible tumor response following radiotherapy.Clinical Trial Registration Number NCT04899908.Clinical Trial Registration Date 25/05/2021.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Encefálicas
/
Imagen por Resonancia Magnética
/
Gadolinio
Idioma:
En
Revista:
Sci Rep
Año:
2024
Tipo del documento:
Article